Vera Therapeutics Inc
VERA50.640USD
-0.530-1.04%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
3.24BMarket Cap
LossP/E TTM
More Details of Vera Therapeutics Inc Company
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
Vera Therapeutics Inc Info
Ticker SymbolVERA
Company nameVera Therapeutics Inc
IPO dateMay 14, 2021
CEOFordyce (Marshall)
Number of employees112
Security typeOrdinary Share
Fiscal year-endMay 14
Address2000 Sierra Point Parkway, Suite 1200
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone16507700077
Websitehttps://veratx.com/
Ticker SymbolVERA
IPO dateMay 14, 2021
CEOFordyce (Marshall)
Company Executives of Vera Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Mr. James R. Meyers
Mr. James R. Meyers
Director
Director
--
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
Mr. David Louis Johnson
Mr. David Louis Johnson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Sean P. Grant
Mr. Sean P. Grant
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kimball Hall
Ms. Kimball Hall
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Mr. James R. Meyers
Mr. James R. Meyers
Director
Director
--
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
8.87%
Longitude Capital Management Co., LLC
7.35%
Kynam Capital Management LP
5.75%
BlackRock Institutional Trust Company, N.A.
5.42%
Deerfield Management Company, L.P.
5.20%
Other
67.41%
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
8.87%
Longitude Capital Management Co., LLC
7.35%
Kynam Capital Management LP
5.75%
BlackRock Institutional Trust Company, N.A.
5.42%
Deerfield Management Company, L.P.
5.20%
Other
67.41%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.17%
Investment Advisor
27.79%
Investment Advisor/Hedge Fund
24.93%
Venture Capital
11.68%
Research Firm
2.46%
Individual Investor
0.95%
Bank and Trust
0.73%
Pension Fund
0.32%
Sovereign Wealth Fund
0.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
391
70.61M
110.50%
-6.46M
2025Q2
381
74.82M
117.74%
-3.10M
2025Q1
382
72.82M
114.18%
-4.50M
2024Q4
363
73.64M
115.55%
+5.56M
2024Q3
344
64.32M
116.69%
-4.00M
2024Q2
326
63.69M
115.63%
-1.15M
2024Q1
280
61.43M
112.19%
+9.50M
2023Q4
210
49.91M
111.09%
+1.94M
2023Q3
190
48.72M
112.47%
-1.60M
2023Q2
180
47.50M
110.63%
+142.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avoro Capital Advisors LLC
6.30M
9.87%
+598.10K
+10.49%
Jun 30, 2025
Longitude Capital Management Co., LLC
5.14M
8.06%
--
--
Oct 31, 2024
Kynam Capital Management LP
3.43M
5.37%
+1.03M
+42.79%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.72M
5.83%
+132.25K
+3.69%
Jun 30, 2025
Deerfield Management Company, L.P.
3.35M
5.25%
+2.30M
+218.87%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.41M
6.92%
-281.24K
-5.99%
Jun 30, 2025
The Vanguard Group, Inc.
2.99M
4.69%
+82.69K
+2.84%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.91M
4.56%
-322.20K
-9.97%
Jun 30, 2025
Eversept Partners, LP
2.38M
3.73%
+484.25K
+25.50%
Jun 30, 2025
Sofinnova Investments, Inc
2.79M
4.38%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
State Street SPDR S&P Biotech ETF
0.81%
ALPS Medical Breakthroughs ETF
0.76%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
Optimize Strategy Index ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.18%
Fidelity Enhanced Small Cap ETF
0.15%
T Rowe Price Small-Mid Cap ETF
0.14%
iShares Biotechnology ETF
0.12%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
State Street SPDR S&P Biotech ETF
Proportion0.81%
ALPS Medical Breakthroughs ETF
Proportion0.76%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.37%
Optimize Strategy Index ETF
Proportion0.26%
ProShares Ultra Nasdaq Biotechnology
Proportion0.26%
Invesco Nasdaq Biotechnology ETF
Proportion0.18%
Fidelity Enhanced Small Cap ETF
Proportion0.15%
T Rowe Price Small-Mid Cap ETF
Proportion0.14%
iShares Biotechnology ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vera Therapeutics Inc?
The top five shareholders of Vera Therapeutics Inc are:
Avoro Capital Advisors LLC holds 6.30M shares, accounting for 9.87% of the total shares.
Longitude Capital Management Co., LLC holds 5.14M shares, accounting for 8.06% of the total shares.
Kynam Capital Management LP holds 3.43M shares, accounting for 5.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.72M shares, accounting for 5.83% of the total shares.
Deerfield Management Company, L.P. holds 3.35M shares, accounting for 5.25% of the total shares.
Avoro Capital Advisors LLC holds 6.30M shares, accounting for 9.87% of the total shares.
Longitude Capital Management Co., LLC holds 5.14M shares, accounting for 8.06% of the total shares.
Kynam Capital Management LP holds 3.43M shares, accounting for 5.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.72M shares, accounting for 5.83% of the total shares.
Deerfield Management Company, L.P. holds 3.35M shares, accounting for 5.25% of the total shares.
What are the top three shareholder types of Vera Therapeutics Inc?
The top three shareholder types of Vera Therapeutics Inc are:
Avoro Capital Advisors LLC
Longitude Capital Management Co., LLC
Kynam Capital Management LP
Avoro Capital Advisors LLC
Longitude Capital Management Co., LLC
Kynam Capital Management LP
How many institutions hold shares of Vera Therapeutics Inc (VERA)?
As of 2025Q3, 391 institutions hold shares of Vera Therapeutics Inc, with a combined market value of approximately 70.61M, accounting for 110.50% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.25%.
What is the biggest source of revenue for Vera Therapeutics Inc?
In --, the -- business generated the highest revenue for Vera Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
